Showing posts with label Aptamers Market. Show all posts
Showing posts with label Aptamers Market. Show all posts

Tuesday, 21 February 2017

Global Aptamer Market: Advancements in Aptamer Technology to Expand Market at 73.1% CAGR

Aptamers Market: Snapshot
Aptamers offer immense potential for the development of unique applications in the field of fundamental research, drug selection, clinical diagnosis, and therapies. They have gained worldwide preference over antibodies owing to the former’s key benefits – greater binding affinity, high specificity, and the ability to not destroy neighboring cells. The major factors driving the aptamers market is growing interest of research scientists in the field of aptamer technology and increasing support from private organizations. On the flip side, lack of knowledge about this technology results in low acceptance. Moreover, ethical issues and inadequate regulatory policies related to aptamer technology threaten to impede the growth of this market.
The worldwide market for aptamers is slated to exhibit an impressive CAGR of 73.1% during the course of the forecast period, rising to a value of US$4.3 bn by 2019.
Growing Application of Aptamers in Therapeutics
Accounting for the leading share by type, nucleic acid aptamers are anticipated to present an opportunity worth US$3.3 bn by 2019, developing at an astounding CAGR of 73.4% during the forecast period. Nucleic acid aptamers have been gaining much traction as a substitute for protein-based targeting approaches. This segment is also projected to be driven by a rising number of leading players collaborating with various organizations and research institutes in order to develop customized nucleic acid aptamers. The introduction of novel selection processes and advanced technology-based aptamers.
On the basis of application, therapeutics is slated to enjoy the dominant share in the aptamers market, registering a strong CAGR of 80.3% during the forecast period to amount to an estimated US$1.4 bn by 2019. The use of aptamers has revolutionized the field of therapeutic development and a number of companies are working toward developing different aptamers for the treatment of a variety of diseases. This is a key factor boosting the uptake of aptamers in therapeutics. Other applications of aptamers include diagnostics and research.
Consistent Collaborations and Investments in R&D to Lend Asia Pacific a Helping Hand
The global market for aptamers is segmented on the basis of geography into Europe, North America, Asia Pacific, and Rest of the World. At the start of the forecast period, North America accounted for more than two-fifth of the overall aptamers market, driven by the strong presence of established companies and growing investments made by them in the field. Europe followed suit, powered by the rising usage of aptamer technologies by small-scale industries. Growth of the aptamers market in this region can also be attributed to consistent efforts and collaborations by players in order to enter the market.
Asia Pacific is projected to witness strong growth by 2019 thanks to impressive investments in R&D, backed by encouraging policies by various governments for the expansion of the pharmaceutical sector. The growing incidence of chronic disorders, such as Alzheimer’s and HIV/AIDS, in APAC has upped the demand for novel therapeutics, which in turn drives the demand for aptamers. Brimming with opportunities in pharmaceutical and diagnostics, the aptamers market in Asia Pacific is sure to attract a lot of attention in the years to come as key players continue to expand and increase product distribution in China, India, and other lucrative countries.
Some of the prominent companies competing in the global aptamers market are Base Pair Biotechnologies, Inc., Vivonics, Inc., SomaLogic Inc., Aptagen, LLC, Aptus Biotech S.L., NeoVentures Biotechnology, Aptamer Solutions Ltd, TriLink BioTechnologies, Inc., AM Biotechnologies, LLC, and Aptamer Sciences, Inc. There is a high degree of rivalry among the key players and this has brought about a surge in investments for the development of novel aptamers.

Monday, 6 February 2017

Increasing Research and Development Activities to Put Global Aptamers Market on Growth Track

Aptamers are chemically synthesized single stranded oligonucleotides that are used to inhibit variety of target proteins and antigens. Aptamers specifically bind to a range of micromolar to macromolar molecular targets. They are basically of two types namely nucleic acid aptamers and peptide aptamers. Nucleic acid aptamers have the strand of oligonucleotides while peptide aptamers contain short peptide domain in its structure. Normally aptamers can be generated by the aptamer selection process known as SELEX process. Aptamer technology applies in number of areas such as diagnostics, food safety, research applications and therapeutics in number of industrial sectors like pharmaceutical, research laboratories and biotechnology.
Transparency Market Research, a leading U.S based market research firm analyses the global market for aptamers and estimates the CAGR of 73.1% for the period 2013 – 2019. This is majorly due to increasing research and development activities by scientists coupled with increasing participation of government and private organizations in the U.S. and U.K. towards the development of this field. For example, in June 2014, Somalogic, Inc. received funding from Bill and Melinda Gates Foundation to develop SOMAmer based tuberculosis biomarker assay for the identification of patient’s tuberculosis.
The other factors such as advancement in aptamer selection technologies coupled with various advantages of aptamers over monoclonal antibodies will further drive the market growth. Several modifications of the SELEX procedure have been introduced to improve aptamer selectivity or to reduce selection time. Subtractive SELEX, automated SELEX and atomic force microscopy-SELEX are some of the modified SELEX processes available for aptamer selection with desired features. Companies like Archemix, Somalogic, Inc. and Aptamer Sciences, Inc. are constantly involved in collaboration strategy with number of biotechnology companies to develop their aptamer business. For example, Archemix collaborated with Elan to discover aptamers for treatment of autoimmune diseases. Thus, these types of collaboration will help companies to develop new aptamers hence drives the market growth. Moreover, large number companies have increased their research expenses on aptamers after first aptamer- Macugen approved by USFDA in 2004. For example, Germany-based NOXXAN Pharma AG has three aptamers namely NOX-E63, NOX A-12 and NOX-H94 under clinical pipeline. NOX-E63 and NOX A-12 are under phase II clinical studies. The approval of these aptamers in future would definitely boost the market growth of aptamers. Other features of aptamers like favorable toxicological property, high stability, ease of synthesis and rapid tissue penetration would significantly contribute to the growth of the market.
The factors mentioned above are driving the development and commercialization of aptamers worldwide. However, unfavorable regulatory environment, lack of universal rule coupled with lack of knowledge of aptamers among research scientists will restrain the market growth. For example, there is no formal regulatory guideline that can satisfactorily address the quality and safety of aptamer molecule. Additionally, countries like Europe demands tedious documentation to start clinical trials on aptamers which will further restrain the market growth of aptamers.

Wednesday, 1 February 2017

Aptamers Market grows with Rising support and participation of private organizations aiming to increase advancements in aptamer field

The growing use of aptamers in drug discovery, pharmaceutical studies, as well as disease treatment will help drive the global aptamers market through the current decade, says Transparency Market Research in a recent study. The report is titled ‘Aptamers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019.’ According to the report, the global aptamers market was valued at US$93.0 million in 2012, and it is expected that the market will reach a valuation of US$4,333.0 million by 2019. This translates to a remarkable CAGR of 73.1% between 2013 and 2019.
However, the report also warns that the growth in the global aptamers market will be restrained to some extent ethical issues associated with aptamers derived from animals. This drawback will be further compounded by strict regulatory mandates designed around aptamers. However, these drawbacks can be overcome by companies in the global aptamers market by modifying aptamers chemistry. For instance, animal-derived aptamers can be replaced by aptamers obtained via the in-vitro process.
For the purpose of this study, the global aptamers market is segmented on the basis of types, applications, and geography. The types of aptamers studied in the report include peptide and nucleic acid aptamers. The segment of nucleic acid aptamers was not only the largest as of 2012, but is also expected to be the fastest growing over the report’s forecast period. This is chiefly owing to the widespread use of nucleic acid aptamers in the R&D sector.
Likewise, the applications analyzed in the report are: Diagnostics, therapeutics development, research and development, and others. Of these, the diagnostics segment will report consistent growth over the next four years as the demand for aptamers for biomedical diagnostics, biomarker development, and molecular imaging remains steady. However, in terms of pace of growth, therapeutics development applications will outpace all other application segments over the report’s forecast period.
From the geographical standpoint, the aptamers market for the following regions is studied: North America, Asia Pacific, Europe, and Rest of the World. Thanks to several key players in the aptamers market being based in the United States, the North America region was identified as the largest market for aptamers in 2012. This factor also creates an environment that fosters R&D related to aptamers.
The Europe aptamers market was the second largest from the global standpoint. According to the findings of the report, Europe constituted about 35% of the global aptamers market in 2012. Small scale industries play a key role in keeping the Europe aptamers market firmly on the growth track. The Asia Pacific market is currently brimming with opportunities in diagnostics and pharmaceuticals, enabling the region to post the highest CAGR between 2013 and 2019.
TMR’s report also conducts a detailed analysis of the competitive scenario in the global aptamers market, which is characterized by intense competition. A high degree of competition has stimulated higher investments the development of novel aptamers. Leading market participants include: Somalogic, Inc., Aptamer Science, Inc. NOXXAN Pharma AG, and Aptagen, Inc.